Breast cancer represents a major threat to women's health in China. Its continuously rising incidence contributes to a growing disease burden, thereby creating a critical demand for novel and effective therapeutic strategies. In recent years, poly ADP‐ribose polymerase (PARP) inhibitors, as a novel class of anti‐tumor drugs targeting the DNA damage repair pathway, have demonstrated remarkable efficacy in treating breast cancer with BRCA1/2 mutations. By selectively inhibiting DNA repair in tumor cells, these agents induce a “synthetic lethality” effect, offering a new option for precision therapy. Currently, PARP inhibitors such as Olaparib and Fluzoparib have been approved for clinical use. This consensus, based on the latest evidence‐based medical data, provides guidance on the standardized application and safety management of PARP inhibitors in breast cancer treatment, aiming to serve as a reference for clinical practice.